O	0	3	Ras	Ras	NN	B-NP
O	4	7	p21	p21	NN	I-NP
O	8	12	onco	onco	AFX	O
O	12	13	-	-	HYPH	O
O	13	20	protein	protein	NN	B-NP
O	21	23	in	in	IN	B-PP
O	24	27	the	the	DT	B-NP
B-Organism_substance	28	32	sera	serum	NNS	I-NP
O	33	35	of	of	IN	B-PP
O	36	40	mice	mouse	NNS	B-NP
O	41	49	carrying	carry	VBG	B-VP
O	50	52	an	an	DT	B-NP
O	53	67	experimentally	experimentally	RB	I-NP
O	68	75	induced	induce	VBN	I-NP
B-Cancer	76	81	tumor	tumor	NN	I-NP
O	82	85	and	and	CC	B-PP
O	86	88	in	in	IN	B-PP
O	89	94	human	human	JJ	B-NP
B-Cancer	95	101	cancer	cancer	NN	I-NP
O	102	110	patients	patient	NNS	I-NP
O	110	111	.	.	.	O

O	113	115	We	We	PRP	B-NP
O	116	120	have	have	VBP	B-VP
O	121	132	established	establish	VBN	I-VP
O	133	134	a	a	DT	B-NP
O	135	140	model	model	NN	I-NP
O	141	147	system	system	NN	I-NP
O	148	150	to	to	TO	B-VP
O	151	157	detect	detect	VB	I-VP
O	158	161	the	the	DT	B-NP
O	162	170	presence	presence	NN	I-NP
O	171	173	of	of	IN	B-PP
O	174	177	ras	ras	NN	B-NP
O	178	181	p21	p21	NN	I-NP
O	182	184	in	in	IN	B-PP
O	185	188	the	the	DT	B-NP
B-Organism_substance	189	193	sera	serum	NNS	I-NP
O	194	196	of	of	IN	B-PP
O	197	201	Balb	Balb	NN	B-NP
O	201	202	/	/	SYM	O
O	202	203	c	c	NN	B-NP
O	204	208	mice	mouse	NNS	I-NP
O	209	217	carrying	carry	VBG	B-VP
B-Cancer	218	224	tumors	tumor	NNS	B-NP
O	225	232	induced	induce	VBN	B-VP
O	233	235	by	by	IN	B-PP
O	236	237	a	a	DT	B-NP
O	238	243	mouse	mouse	NN	I-NP
B-Cell	244	248	cell	cell	NN	I-NP
I-Cell	249	253	line	line	NN	I-NP
O	254	265	transformed	transform	VBN	B-VP
O	266	270	with	with	IN	B-PP
O	271	274	the	the	DT	B-NP
O	275	281	Harvey	Harvey	NNP	I-NP
O	282	288	murine	murine	JJ	I-NP
O	289	296	sarcoma	sarcoma	NN	I-NP
O	297	302	virus	virus	NN	I-NP
O	303	305	in	in	IN	B-PP
O	306	309	the	the	DT	B-NP
O	310	318	presence	presence	NN	I-NP
O	319	321	of	of	IN	B-PP
O	322	323	a	a	DT	B-NP
O	324	330	helper	helper	NN	I-NP
O	331	337	Friend	Friend	NN	I-NP
O	338	344	murine	murine	JJ	I-NP
O	345	353	leukemia	leukemia	NN	I-NP
O	354	359	virus	virus	NN	I-NP
O	359	360	.	.	.	O

O	361	363	As	As	IN	B-SBAR
O	364	374	determined	determine	VBN	B-VP
O	375	377	by	by	IN	B-PP
O	378	383	ELISA	ELISA	NN	B-NP
O	384	387	and	and	CC	I-NP
O	388	398	immunoblot	immunoblot	NN	I-NP
O	399	405	assays	assay	NNS	I-NP
O	405	406	,	,	,	O
O	407	410	ras	ras	NN	B-NP
O	411	414	p21	p21	NN	I-NP
O	415	417	in	in	IN	B-PP
O	418	421	the	the	DT	B-NP
B-Organism_substance	422	427	serum	serum	NN	I-NP
O	428	437	increased	increase	VBD	B-VP
O	438	442	with	with	IN	B-PP
O	443	452	increased	increase	VBN	B-NP
B-Cancer	453	458	tumor	tumor	NN	I-NP
O	459	465	growth	growth	NN	I-NP
O	465	466	.	.	.	O

O	467	472	Since	Since	IN	B-SBAR
O	473	476	ras	ras	NN	B-NP
O	477	482	genes	gene	NNS	I-NP
O	483	487	have	have	VBP	B-VP
O	488	492	been	be	VBN	I-VP
O	493	498	found	find	VBN	I-VP
O	499	501	to	to	TO	I-VP
O	502	504	be	be	VB	I-VP
O	505	515	frequently	frequently	RB	I-VP
O	516	525	activated	activate	VBN	I-VP
O	526	528	in	in	IN	B-PP
O	529	534	human	human	JJ	B-NP
B-Cancer	535	542	tumours	tumour	NNS	I-NP
O	542	543	,	,	,	O
O	544	546	we	we	PRP	B-NP
O	547	555	examined	examine	VBD	B-VP
O	556	559	the	the	DT	B-NP
O	560	566	levels	level	NNS	I-NP
O	567	569	of	of	IN	B-PP
O	570	573	ras	ras	NN	B-NP
O	574	577	p21	p21	NN	I-NP
O	578	580	in	in	IN	B-PP
O	581	584	the	the	DT	B-NP
B-Organism_substance	585	589	sera	serum	NNS	I-NP
O	590	592	of	of	IN	B-PP
O	593	594	a	a	DT	B-NP
O	595	602	variety	variety	NN	I-NP
O	603	605	of	of	IN	B-PP
O	606	611	human	human	JJ	B-NP
B-Cancer	612	618	cancer	cancer	NN	I-NP
O	619	627	patients	patient	NNS	I-NP
O	627	628	.	.	.	O

O	629	631	In	In	IN	B-PP
O	632	636	only	only	RB	B-NP
O	637	638	3	3	CD	I-NP
O	639	642	out	out	IN	I-NP
O	643	645	of	of	IN	I-NP
O	646	648	13	13	CD	I-NP
O	649	654	cases	case	NNS	I-NP
O	654	655	,	,	,	O
O	656	668	representing	represent	VBG	B-VP
O	669	677	patients	patient	NNS	B-NP
O	678	682	with	with	IN	B-PP
B-Cancer	683	698	adenocarcinomas	adenocarcinoma	NNS	B-NP
O	699	701	of	of	IN	B-PP
O	702	705	the	the	DT	B-NP
B-Organ	706	713	stomach	stomach	NN	I-NP
O	714	723	receiving	receive	VBG	B-VP
O	724	736	chemotherapy	chemotherapy	NN	B-NP
O	736	737	,	,	,	O
O	738	741	was	be	VBD	B-VP
O	742	745	ras	ras	NN	B-NP
O	746	749	p21	p21	NN	I-NP
O	750	758	detected	detect	VBN	B-VP
O	759	761	at	at	IN	B-PP
O	762	770	elevated	elevated	JJ	B-NP
O	771	777	levels	level	NNS	I-NP
O	777	778	,	,	,	O
O	779	786	whereas	whereas	IN	O
O	787	789	in	in	IN	B-PP
O	790	798	patients	patient	NNS	B-NP
O	799	803	with	with	IN	B-PP
O	804	807	the	the	DT	B-NP
O	808	817	following	follow	VBG	I-NP
O	818	823	types	type	NNS	I-NP
O	824	826	of	of	IN	B-PP
B-Cancer	827	833	cancer	cancer	NN	B-NP
O	834	836	no	no	DT	B-NP
O	837	848	substantial	substantial	JJ	I-NP
O	849	855	change	change	NN	I-NP
O	856	858	in	in	IN	B-PP
B-Organism_substance	859	864	serum	serum	NN	B-NP
O	865	868	ras	ras	NN	I-NP
O	869	872	p21	p21	NN	I-NP
O	873	876	was	be	VBD	B-VP
O	877	885	observed	observe	VBN	I-VP
O	885	886	;	;	:	O
O	887	891	nine	nine	CD	B-NP
O	892	896	with	with	IN	B-PP
B-Cancer	897	903	breast	breast	NN	B-NP
O	903	904	,	,	,	O
O	905	906	5	5	CD	B-NP
B-Cancer	907	912	colon	colon	NN	I-NP
O	912	913	,	,	,	O
O	914	915	5	5	CD	B-NP
B-Cancer	916	920	lung	lung	NN	I-NP
O	920	921	,	,	,	O
O	922	923	5	5	CD	B-NP
B-Cancer	924	931	ovarian	ovarian	JJ	I-NP
O	932	935	and	and	CC	O
O	936	937	5	5	CD	B-NP
B-Cancer	938	952	hepatocellular	hepatocellular	JJ	I-NP
I-Cancer	953	963	carcinomas	carcinoma	NNS	I-NP
O	963	964	.	.	.	O

